Rhythm Pharmaceuticals (RYTM) Financial Analysis & Valuation | Quarter Chart
Rhythm Pharmaceuticals (RYTM)
RYTMPrice: $110.04
Fair Value: 🔒
🔒score
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatmen... more
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the developme... more
Description
Shares
| Market Cap | $7.55B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Meeker |
| IPO Date | 2017-10-09 | CAGR | — |
| Employees | 283 | Website | www.rhythmtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
RYTM chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.48B | P/E Ratio | -35.16 |
| Forward P/E | -148.43 | PEG Ratio | — |
| P/S Ratio | 108.37 | P/B Ratio | 189.99 |
| P/CF Ratio | -195.48 | P/FCF Ratio | -195.58 |
| EPS | $-3.13 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 58.67% | Gross Margin | 0.89% |
| Operating Margin | -0.91% | Profit Margin | -0.93% |
| ROE | -2.03% | ROA | -0.46% |
| ROCE | -0.58% | Current Ratio | 4.17 |
| Quick Ratio | 3.89 | Cash Ratio | 0.6 |
| Debt/Equity | 1.85 | Interest Coverage | -9.99 |
| Altman Z Score | 9.8 | Piotroski Score | 3 |